Lexaria Bioscience Corp Stock Cash And Equivalents
| LEXX Stock | USD 2.13 0.02 0.93% |
Lexaria Bioscience Corp fundamentals help investors to digest information that contributes to Lexaria Bioscience's financial success or failures. It also enables traders to predict the movement of Lexaria Stock. The fundamental analysis module provides a way to measure Lexaria Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexaria Bioscience stock.
Lexaria | Cash And Equivalents |
Lexaria Bioscience Corp Company Cash And Equivalents Analysis
Lexaria Bioscience's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Lexaria Bioscience Cash And Equivalents | 7.34 M |
Most of Lexaria Bioscience's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexaria Bioscience Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lexaria Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Lexaria Bioscience is extremely important. It helps to project a fair market value of Lexaria Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Lexaria Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexaria Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexaria Bioscience's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Lexaria Bioscience Corp has 7.34 M in Cash And Equivalents. This is 99.11% lower than that of the Biotechnology sector and 98.36% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.73% higher than that of the company.
Lexaria Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexaria Bioscience's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexaria Bioscience could also be used in its relative valuation, which is a method of valuing Lexaria Bioscience by comparing valuation metrics of similar companies.Lexaria Bioscience is currently under evaluation in cash and equivalents category among its peers.
Lexaria Bioscience Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lexaria Bioscience from analyzing Lexaria Bioscience's financial statements. These drivers represent accounts that assess Lexaria Bioscience's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lexaria Bioscience's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 12.4M | 27.3M | 17.4M | 6.9M | 115.2M | 120.9M | |
| Enterprise Value | 11.3M | 16.5M | 11.7M | 5.8M | 116.4M | 122.2M |
Lexaria Bioscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lexaria Bioscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lexaria Bioscience's managers, analysts, and investors.Environmental | Governance | Social |
Lexaria Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (20.75) % | ||||
| Current Valuation | 29.16 M | ||||
| Shares Outstanding | 17.45 M | ||||
| Shares Owned By Insiders | 7.00 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 277.08 K | ||||
| Price To Book | 3.71 X | ||||
| Price To Sales | 91.29 X | ||||
| Revenue | 226.21 K | ||||
| Gross Profit | 183.56 K | ||||
| EBITDA | (6.39 M) | ||||
| Net Income | (6.71 M) | ||||
| Cash And Equivalents | 7.34 M | ||||
| Cash Per Share | 1.23 X | ||||
| Total Debt | 163.97 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 40.09 X | ||||
| Book Value Per Share | 0.64 X | ||||
| Cash Flow From Operations | (5.88 M) | ||||
| Short Ratio | 2.62 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 10.0 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 37.52 M | ||||
| Total Asset | 3.08 M | ||||
| Retained Earnings | (45.76 M) | ||||
| Working Capital | 1.93 M | ||||
| Net Asset | 3.08 M |
About Lexaria Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lexaria Bioscience Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexaria Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexaria Bioscience Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.